IO RESISTANT SQNSCLC

Clinical trials for IO RESISTANT SQNSCLC explained in plain language.

Never miss a new study

Get alerted when new IO RESISTANT SQNSCLC trials appear

Sign up with your email to follow new studies for IO RESISTANT SQNSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for Tough-to-Treat lung cancer: experimental drug takes on standard chemo

Disease control Recruiting now

This study is testing whether a new drug called IBI363 works better than standard chemotherapy (docetaxel) for people with advanced squamous non-small cell lung cancer. It's for adults whose cancer has continued to grow despite receiving both platinum-based chemotherapy and immun…

Matched conditions: IO RESISTANT SQNSCLC

Phase: PHASE3 • Sponsor: Fortvita Biologics (USA)Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:35 UTC

IO RESISTANT SQNSCLC

Get alerted when new IO RESISTANT SQNSCLC trials appear

New hope for Tough-to-Treat lung cancer: experimental drug takes on standard chemo